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Abstract 
Background: Neuroendocine carcinoma of the gynecologic tract is rare and poses a 
significant clinical challenge because of tumor heterogeneity and lack of 
standardized guidelines for treatment. Ovotestis refers to the histology of a gonad 
that contains both ovarian follicles and testicular tubular elements. Ovotesticular 
disorder of sexual development occurs in fewer than 10% of all disorders of sexual 
development. Gonadal tumors with malignant potential occur in 2.6% of all cases of 
ovotesticular disorder of sexual development. 
Case: Here we represent a 77-year-old woman with primary amenorrhea, infertility 
and 10cm solid mass in left adnex with 46 XY in karyotype with ovotestis 
neuroendocrine neoplasm in pathology report which was treated with a multi-
modality manner including surgery and chemotherapy but she came back with 
pulmonary metastasis after 2 cycles of chemotherapy. For women who present with 
a stage 1 primary ovarian neuroendocrine tumor the prognosis is excellent with 
greater than 90% survival. Neuroendocrine tumor of the ovary represents 3 % of all 
neuroendocrine tumors. The prevalence of ovotestis is 1/20000 births. For women 
with more advanced disease, the prognosis is poor. Neuroendocrine carcinoma of the 
ovary is a rare and aggressive tumor commonly associated with other surface 
epithelial and germ cell neoplasms. The prevalence of ovotestis is 1/20000 births 
and gonadal malignancies are the most reported neoplasm affected the ovotestis. 
Here we report a case of ovotestis which is presented with neuroendocrine 
carcinoma and poor prognosis.  
Conclusion: Neuroendocrine carcinoma of the ovary is a rare and aggressive tumor 
commonly associated with other surface epithelial and germ cell neoplasms. The 
prevalence of ovotestis is rare and gonadal malignancies are the most reported 
neoplasm affected the ovotestis.  
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Introduction 
 
euroendocrine carcinomas (NECS) 
are originated from endocrine cells 
of the diffuse neuroendocrine 
system, which are mainly from gastrointestinal 
tract, lungs and pancreas (1). Neuroendocrine 
neoplasms of the testis are unusual tumors 
and represent more than 1% of all testicular 
tumors (2). They are rarely seen in the female 
genital system, and most commonly in the 
ovaries and cervix. NEC occurs very 
exceptional in another part of the genital trace 
(e.g, the endometrium or vagina) (3). An 
analysis of the SEER database shows that the 
incidence of neuroendocrine tumor is 
increasing (1). 
Tumor differentiation and tumor grade often 
are correlated with mitotic count and Ki-67 
proliferation index (4). In most cases, well-
differentiated, low grade tumors have a mitotic 
count of less than 2/10 high-power field (HPF) 
and Ki67 index of less than 3%. Well 
differentiated intermediate-grade tumors 
usually have a mitotic count of 2 to 20/10 HPF 
and/or a Ki-67 index of 3-20%. In high-grade 
tumors, the mitotic count usually exceeds 
20/10 HPF and/or the Ki-67 exceeds 20% (4). 
In addition the margin status (Negative or 
positive), the presence of vascular or 
perineural invasion should be included in the 
pathology report, which has been suggested 
that these factors may also have prognostic 
significance (5). 
N 
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In the recent decade, there has been an 
increased incidence of neuroendocrine 
tumors: which may reflect improvements in 
standardized classification criteria, and 
diagnostic recognition (1). Genital 
neuroendocrine tumors are rare, with limited 
prospective data to guide management. 
Resection is the primary treatment approach 
for localized low-grade neuroendocrine tumors 
with close follow-up. Whether patients with 
intermediate grade tumors should receive 
additional therapy remains a choice based on 
the individual clinical analysis (6). 
Ovotesticular is characterized by the 
presence of ovarian and testicular tissues in 
the same individual. Most cases have a 46,XX 
karyotype, while 7% have 46,XY karyotype 
and 10-40% exhibit chromosomal mosaicism. 
Many patients with ovotesticular disorder have 
a uterus. Müllerian duct structures typically 
have developed on the gonad side(s) not with 
no testicular tissue. The gonads may be 
ovotestis, or they may be a combination of an 
ovary on one side and a testis or ovotestis on 
the other side (7). 
Here we present a case of neuroendocrine 
tumor of ovotestis and its presentation, 
pathologic and genetic findings, and 
management.  
 
Case report 
 
A 77-year-old woman with a history of 
primary amenorrhea and infertility was 
admitted for pelvic pain. In pelvic exam, the 
patient had was a phenotypically developed 
female with normal external male genitalia 
and there was fullness in left adnex. 
Abdomino pelvic Computed Tomography (CT) 
scan and sonography showed a 10 cm solid 
mass in left adnex without any metastasis. 
Complete blood count and CA 125 tumor 
marker were analyzed. All laboratory tests 
showed normal range.  
During the laparotomy we observed a left 
adnex mass of 7×10 cm in diameter and an 
atrophic uterus with a 1.5 cm myoma without 
cervix separate from the left adnex and a 
small mass in right adnex. A left 
oophorectomy was performed and sent for 
frozen section and pathology review after that 
hystrectomy and right oophorectomy was 
performed. Histopathologic examination 
revealed bellow: pelvic mass resection, frozen 
and final diagnosis (Figure 1):  
• Neuroendocrine tumor 
• Tumor size: 8.75 cm 
• Tumor is limited to capsule  
• No vascular or prineural invasion is seen. 
• Mitosis count 12 per 10 HPF (intermediate-
grade tumors). 
• Ki 67: Nuclear positivity in 30% of tumor 
cells and remnant of uterus, immature 
testis, ovotestis with immature seminiferous 
tubules. Intra abdominal fluid cytology and 
omental tissue was negative for 
malignancy. 
• karyotype was 46XY which verified the 
ovotestis. 
Adjuvant chemotherapy with 6 cycles 
Etoposide + cisplatine were then administered 
but pulmonary metastasis has been happened 
after two course of chemotherapy. Based on 
medical Ethics Committee of Shahid Beheshti 
University of Medical Sciences, a written 
informed consent was obtained from the 
patient for publication of this article and 
accompanying images.  
 
 
 
Figure 1. Neuroendocrine neoplasm: small nests in rich vascular background. Cells have finely granular amphophilic cytoplasm. 
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Discussion 
 
Lee et al presented a 40-year-old woman 
with a 30 cm pelvic mass. After the operation, 
she was diagnosed of stageIa NEC of left 
ovary. The patient received six cycles of 
paclitaxel-carboplatin chemotherapy 
postoperative similar to this case report 
primary neuroendocrine carcinoma presented 
with an adnexal mass (8). Berdjis and 
Mostofiin presented a series of 10 cases of 
carcinoid tumors of the testis: 2 of the patients 
died of 4-6 years (9). 
Zavala-Pompa et al described 3 cases 
described can be categorized as low-grade 
(well-differentiated) tumors, while 1 case likely 
corresponds to an intermediate-grade 
(moderately differentiated) tumors like the 
case which was mentioned in this report (10). 
Crochet et al reported a primary 
neuroendocrine carcinoma of fallopian tube 
which presented with an adenexal mass. They 
performed laparotomy and staging and 
adjuvant chemotherapy 6 cycles of 
carbopatin/ etoposide. She was alive 9 
months after the diagnosis with no evidence of 
relapse (11).  
Like in this case report. primary 
neuroendocrine carcinoma presented with an 
adnexal mass, but pulmonary metastasis has 
been happened during chemotherapy and the 
origin of tumor was ovotestis. Gonadal 
Malignancies are the most reported neoplasm 
affected the ovotestis. Here in our case 
ovotestis is presented with neuroendocrine 
carcinoma.  
 
Conclusion 
 
Primary carcinoid tumors of the ovary 
account for less than 5% of all carcinoid 
tumors and for less than 0.12% of all ovarian 
neoplasms. Neuroendocrine tumor of the 
ovary represents 3% of all neuroendocrine 
tumors. The prevalence of ovotestis is 
1/20000 births. For those patients in whom the 
diagnosis is known. Hysterectomy for early 
stage disease and adjuvant chemotherapy 
with etoposide/ cisplatin even without 
evidence of nodal metastasis should be 
considered as part of a multi-modality 
therapeutic strategy (3). 
Neuroendocrine carcinoma of the ovary is 
a rare and aggressive tumor commonly 
associated with other surface epithelial and 
germ cell neoplasms. The prevalence of 
ovotestis is rare but we should consider it in 
patients with adnexal mass and in patients 
with simptoms like amenorrhea we should 
consider gental system anomalies to 
diagnosis of rare ovarian cancers in early 
stage.  
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